COYA
COYA
NASDAQ · Biotechnology

Coya Therapeutics Inc

$4.96
-0.30 (-5.70%)
As of May 16, 9:41 PM ET ·
Financial Highlights (FY 2026)
Revenue
14.26M
Net Income
-38,087,173
Gross Margin
Profit Margin
-267.1%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 59.4% 59.4% 59.4%
Operating Margin -283.9% -21.4% -22.3% -21.3%
Profit Margin -267.1% -24.1% -19.2% -20.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 14.26M 21.48M 20.04M 21.53M
Gross Profit 12.76M 11.90M 12.79M
Operating Income -40,470,769 -4,588,283 -4,466,509 -4,589,536
Net Income -38,087,173 -5,165,355 -3,853,498 -4,413,133
Gross Margin 59.4% 59.4% 59.4%
Operating Margin -283.9% -21.4% -22.3% -21.3%
Profit Margin -267.1% -24.1% -19.2% -20.5%
Rev Growth -8.7% +0.8% +4.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 20.03M 19.96M 21.21M
Total Equity 82.70M 80.09M 74.44M
D/E Ratio 0.24 0.25 0.29
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -38,033,136 -6,655,427 -5,995,002 -5,792,790
Free Cash Flow -3,535,951 -2,421,928 -4,008,931